A user experienced chest discomfort after taking finasteride for hair loss and is concerned about whether it is a side effect or an allergy. They are advised to consult a doctor and consider other hair loss treatments if necessary.
Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
Finasteride can cause gynecomastia due to hormonal imbalances. Management includes consulting an endocrinologist and using aromatase inhibitors like anastrozole or supplements like DIM and zinc.
Finasteride can cause sexual side effects, and reducing porn and masturbation may help improve sexual function. Some users experience persistent issues even after stopping finasteride.
The conversation discusses coping with hair loss and the emotional impact of balding, with some users finding peace in shaving their heads. Treatments mentioned include minoxidil, finasteride, and lifestyle changes like diet and exercise.
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
Breezula is seen as potentially overhyped, with concerns about its cost, effectiveness, and long-term benefits compared to existing treatments like finasteride and minoxidil. Some users believe it could complement existing treatments, while others are skeptical about its impact and prefer waiting for newer options like GT20029 and PP405.
Kintor Pyrilutamide treatment, a potential hair loss treatment that may become available to the public soon. People have been experimenting with using it in topical form, with mixed results and no reported side effects.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Pyrilutamide is seen as a last hope for those who can't take finasteride, with promising results reported. However, there's uncertainty about the quality and consistency of Pyrilutamide from black market sources.
A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.
The user experienced side effects from finasteride and Nutrafol, opting for non-hormonal treatments like minoxidil, exercise, and a healthy lifestyle. Others discussed using Dutasteride, Biotin, and minoxidil with varying success and side effects.
Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.
Using licorice to counteract the blood pressure-lowering effects of oral minoxidil. Concerns about licorice affecting potassium levels and minoxidil's effectiveness were raised.
The conversation discusses hair thinning and treatments like Minoxidil, finasteride, and RU58841. The user is concerned about distinguishing between natural hair parting and actual thinning.
Switching from topical finasteride to oral Dutasteride and using Fluridil caused persistent testicular discomfort. The discomfort did not subside after stopping Fluridil, raising concerns about Dutasteride's role.
The conversation discusses the scalp tension theory as a potential factor in hair loss, alongside DHT, inflammation, and other mechanisms. Treatments mentioned include finasteride, minoxidil, and botox injections, with some users exploring additional methods due to varying effectiveness.
The user has been using finasteride and minoxidil for 11 months but is experiencing increased hair loss and no signs of improvement. Another user shares a similar experience and mentions iron deficiency and thyroid issues affecting hair loss despite using the treatments.
A user is experiencing significant hair loss and scalp issues despite using Minoxidil, finasteride, and RU58841 since 2017. They switched to oral Minoxidil and are now on isotretinoin and topical corticosteroids for seborrheic dermatitis but continue to lose hair and seek advice on whether inflammation or treatment changes are the cause.
The conversation discusses the effectiveness of Spironolactone and Finasteride for hair regrowth in females. Specific treatments mentioned are Spironolactone and Finasteride.
A 39 year old female who has been taking finasteride for 1.5 months and is experiencing side effects such as muscle and butt shrinkage, and weight loss despite still having tight clothing. The user is seeking advice from those with knowledge of bodybuilding and hormones to help figure out the issue.
Treatments for hair loss, such as Minoxidil, finasteride, RU58841 and Eucapil; the legitimacy of RU58841 products; and safety concerns related to using RU58841.
Minoxidil and finasteride have improved hair thickness and density, but temple areas remain stubborn. Continued use is recommended, with suggestions for topical minoxidil, microneedling, or considering a hair transplant for further improvement.
Feeding bacteria-free mice with Lactobacillus murinus worsened hair loss, but a regular diet with biotin stopped it. The conversation suggests gut bacteria and diet may influence hair loss, with some skepticism and discussion about other factors like DHT and genetics.
User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.
The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.